Guangxi LiuYao Group Co., Ltd (603368.SS) Bundle
Who is buying Guangxi LiuYao Group Co., Ltd (603368.SS) and why are they drawn to it? Investors note the company's long history since 1981 and its role in China's healthcare network, steadying attention from individuals seeking reliable demand for pharmaceutical products; institutions appreciate a remarkably low volatility profile with a beta of 0.366, while value hunters point to a market cap near CNY 7.42 billion and a price-to-earnings ratio around 8.7x, suggesting potential undervaluation; income-focused holders are attracted by a 4.28% dividend yield (ex-dividend date: May 29, 2025) backed by operating cash flow of CNY 839 million and reported net income of CNY 854.87 million, and management's confidence is signaled by the August 22, 2025 repurchase of 4.3738 million shares (1.10% of share capital) at a total cost of RMB 80.7303 million with buy prices between RMB 18.22-18.60-contextualized by a stock price of CNY 17.93 and market cap of CNY 6.98 billion as of November 28, 2025-so read on to see exactly which investor groups are influencing the stock and how these concrete metrics shape sentiment and strategy.
Guangxi LiuYao Group Co., Ltd (603368.SS) Who Invests in Guangxi LiuYao Group Co., Ltd and Why?
Guangxi LiuYao Group Co., Ltd (603368.SS) attracts a mix of investor types drawn to its defensive positioning in China's healthcare sector, steady cash generation, and apparent valuation characteristics.- Individual investors - drawn by stable revenue streams and the company's essential role in regional healthcare; consistent demand for pharmaceutical products underpins predictable sales and earnings.
- Institutional investors (mutual funds, pension funds) - attracted by a low beta of 0.366, signaling lower volatility versus the broader market and suitability for risk-averse allocations.
- Long-term investors - value the company's established history (founded 1981) and regional dominance in Guangxi, viewing it as a defensive healthcare holding.
- Value investors - see potential undervaluation given a market capitalization of approximately CNY 7.42 billion and a price-to-earnings ratio near 8.7x.
- Dividend-seeking investors - target the company for a dividend yield of 4.28% with an ex-dividend date of May 29, 2025, supporting income strategies.
- Cash-flow focused investors - encouraged by operating cash flow of CNY 839 million, which supports operations and dividend sustainability.
| Metric | Value |
|---|---|
| Market Capitalization | CNY 7.42 billion |
| Price-to-Earnings (P/E) | ~8.7x |
| Beta (3y) | 0.366 |
| Dividend Yield | 4.28% |
| Ex-Dividend Date | May 29, 2025 |
| Operating Cash Flow (latest) | CNY 839 million |
| Founded | 1981 |
| Regional Focus | Guangxi (regional dominance) |
- Portfolio roles: defensive core holding for conservative equity exposure, income sleeve for dividend strategies, and a value pick for contrarian/relative-value mandates.
- Risk considerations investors weigh: concentration in regional markets, sector regulatory risk in pharmaceuticals, and growth vs. yield trade-offs.
Institutional Ownership and Major Shareholders of Guangxi LiuYao Group Co., Ltd (603368.SS)
- Share repurchase (as of 2025-08-22): 4.3738 million shares repurchased, representing 1.10% of total share capital.
- Repurchase cost and price band: total cash outflow RMB 80.7303 million; repurchase prices ranged RMB 18.22-18.60 per share.
- Purpose of repurchase: shares reserved for the employee stock ownership plan / equity incentives to align employee and shareholder interests.
- Market context (as of 2025-11-28): market capitalization CNY 6.98 billion; closing stock price CNY 17.93.
- Institutional ownership: no material public disclosures of significant changes in institutional holdings since the repurchase, indicating relatively stable institutional investor confidence.
| Metric | Value | Notes |
|---|---|---|
| Repurchased shares | 4,373,800 | 1.10% of issued share capital |
| Total repurchase cost | RMB 80,730,300 | Average repurchase price ≈ RMB 18.46 |
| Repurchase price range | RMB 18.22 - 18.60 | Executed across the announced window |
| Estimated total shares outstanding (implied) | ~397,618,000 | Derived from repurchase % (4.3738m = 1.10%) |
| Market capitalization (2025-11-28) | CNY 6.98 billion | Stock price CNY 17.93 on that date |
- Signal to the market: the buyback-funded at ~RMB 80.73m and executed near the CNY 18.3-18.6 range-serves as a management signal of confidence in valuation and future cash generation.
- Corporate governance angle: allocating repurchased shares to an employee equity plan ties incentives to long-term shareholder value, commonly viewed favorably by institutional holders.
- Institutional posture: with no public announcements of large-scale entry/exit by institutions, ownership structure appears stable; institutions likely view the buyback and incentive alignment as positive.
Key Investors and Their Impact on Guangxi LiuYao Group Co., Ltd (603368.SS)
- Largest shareholder: State-owned Assets Supervision and Administration Commission of the Government of Guangxi Zhuang Autonomous Region - signals direct state support and potential influence over strategic, capital and governance decisions.
Recent corporate actions and financial metrics that shape investor interest:
- Share repurchase: the company repurchased 4.3738 million shares - a management signal of confidence and a direct mechanism to enhance shareholder value and EPS.
- Market capitalization: CNY 6.98 billion (as of 2025-11-28) - positions the company as a mid-cap healthcare sector player attractive to income- and stability-seeking institutions.
- Profitability: net income of CNY 854.87 million - demonstrates earnings strength and supports dividend/return expectations for conservative investors.
- Volatility profile: beta = 0.366 - materially lower volatility than the broader market, appealing to risk-averse investors and long-term holders.
- Public shareholder landscape: no detailed public disclosures identify other major institutional holders or their specific strategic impacts.
| Metric | Value | Reference / Date |
|---|---|---|
| Largest Shareholder | Guangxi SASAC (State-owned) | Ongoing (public filings) |
| Shares Repurchased | 4,373,800 shares | Company repurchase announcement |
| Market Capitalization | CNY 6.98 billion | 2025-11-28 |
| Net Income (most recent reporting) | CNY 854.87 million | Latest annual/quarterly report |
| Beta (volatility) | 0.366 | Market data |
| Other major institutional holders | Not specifically disclosed | Public filings |
- Investor implications:
- State ownership: likely stability in strategic direction, potential access to regional policy support and preferential government procurement channels.
- Buyback: supports near-term shareholder returns and signals management's view that shares are undervalued.
- Low beta + solid net income: attractive to pension funds, insurance companies and conservative mutual funds seeking defensive healthcare exposure.
For strategic and cultural context that may influence investor sentiment, see: Mission Statement, Vision, & Core Values (2026) of Guangxi LiuYao Group Co., Ltd.
Guangxi LiuYao Group Co., Ltd (603368.SS) Market Impact and Investor Sentiment
Guangxi LiuYao Group's visible market footprint and corporate actions have materially shaped investor perception. The company's market capitalization of CNY 6.98 billion (as of 2025-11-28) and management-led share repurchases signal confidence, while stable earnings and a dependable dividend profile attract a mix of income and defensive investors. Its long-standing role in China's healthcare infrastructure since 1981 reinforces a resilient long-term narrative.- Market capitalization: CNY 6.98 billion (2025-11-28)
- Repurchased shares: 4.3738 million shares (as of 2025-08-22)
- Beta: 0.366 (low volatility vs. market)
- Net income: CNY 854.87 million (most recent reporting period)
- Dividend yield: 4.28% (ex-dividend date 2025-05-29)
- Founded/operating presence: since 1981 - essential to healthcare infrastructure
| Metric | Value | Date / Notes |
|---|---|---|
| Market Capitalization | CNY 6.98 billion | 2025-11-28 |
| Share Repurchases | 4.3738 million shares | Cumulative, as of 2025-08-22 |
| Beta | 0.366 | Lower volatility vs. broader market |
| Net Income | CNY 854.87 million | Most recent reported period |
| Dividend Yield | 4.28% | Ex-dividend date: 2025-05-29 |
| Operational Heritage | Since 1981 | Established healthcare infrastructure player |
- Income-focused retail and institutional investors drawn by the 4.28% yield and predictable payouts
- Risk-averse allocators favoring low-beta stocks for portfolio stability
- Long-term strategic investors valuing an established healthcare provider with steady net income
- Management-aligned shareholders encouraged by the 4.3738 million share repurchase program
Guangxi LiuYao Group Co., Ltd (603368.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.